Trial reportBMC anesthesiology2026
Recommended intravenous infusion rate of sufentanil during induction of general anesthesia to prevent coughing: a randomized, single-blind, prospective clinical trials.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSufentanil-induced cough (SIC) is a prevalent and potentially hazardous reflex during anesthesia induction. While slow injection is known to reduce SIC, the precise dose-response relationship between infusion rate and cough suppression remains poorly defined. This study aimed to identify the optimal intravenous infusion rate of sufentanil to reduce SCI and to estimate the 50% and 95% cough inhibition thresholds (IS₅₀ and IS₉₅) using probit regression analysis.
methodsA total of 70 adult patients (ASA I-II) scheduled for general anesthesia with tracheal intubation were prospectively enrolled and randomized into seven groups according to different sufentanil infusion rates: Group A, 0.20 mL/s; Group B, 0.225 mL/s; Group C, 0.25 mL/s; Group D, 0.275 mL/s; Group E, 0.30 mL/s; Group F, 0.325 mL/s; and Group G, 0.35 mL/s. All patients received sufentanil at a dose of 0.4 µg/kg (concentration: 5 µg/mL). The incidence and severity of coughing, apnea, hypoxemia, and pruritus within 5 min after injection were recorded. Vital signs-including respiratory rate, heart rate, blood pressure, and oxygen saturation-were measured at baseline and 5 min after drug administration. Cough severity was classified as: none (0 coughs), mild (1-2 coughs), moderate (3-4 coughs), and severe (≥ 5 coughs) during the 5-minute observatiototal period.
resultsThe incidence of SIC significantly decreased as the infusion rate slowed (P < 0.001). The SIC incidence for rates 0.35, 0.325, 0.30, 0.275, 0.25, 0.225, and 0.20 mL/s were 73.3%, 46.7%, 46.7%, 33.3%, 40.0%, 0.0%, and 13.3%, respectively. Using Probit analysis, the estimated IS₅₀ for cough suppression was 0.310 mL/s(95% CI: 0.288-0.347) and the IS₉₅ was 0.172 mL/s (95% CI: 0.069-0.212). No episodes of severe glottic closure or opioid-induced chest wall rigidity were observed in any group.
conclusionsTo minimize sufentanil-induced coughing in adult patients with normal airway anatomy (ASA I-II, body mass index 16-26 kg/m²), an infusion rate of ≤ 0.172 mL/s (approximately 46 s for 0.4 µg/kg at 5 µg/mL) is recommended, which achieves about 95% cough prevention according to probit regression analysis. However, respiratory depression and apnea remained frequent in this cohort, underscoring the need for adequate preoxygenation, continuous pulse oximetry and capnography monitoring, and immediate availability of airway management equipment during induction with sufentanil 0.4 µg/kg.
trial registrationChiCTR2300067455 (Registered on 9 January 2023 ): https://www.chictr.org.cn/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.